Targeting STING to disrupt macrophage-mediated adhesion in encapsulating peritoneal sclerosis

Area of Science:

• Fibrotic diseases
• Immunology
• Renal medicine

Background:

• Encapsulating peritoneal sclerosis (EPS) is a severe fibrotic complication of peritoneal dialysis (PD).
• Current treatments for EPS are limited due to an incomplete understanding of its pathogenesis.
• Identifying novel therapeutic targets is crucial for managing EPS.

Purpose of the Study:

• To investigate the role of the STING signaling pathway in the development of PD-induced EPS.
• To explore the potential of STING inhibition as a therapeutic strategy for EPS.

Main Methods:

• Development of a modified mouse model for PD-induced EPS.
• Analysis of STING pathway activation in peritoneal mesothelial cells.
• Assessment of macrophage chemokine (CCL2) secretion and macrophage infiltration.
• Evaluation of the efficacy of STING inhibition (H151) on fibrosis and adhesions.

Main Results:

• STING pathway activation in peritoneal mesothelial cells promotes EPS.
• Activated STING increases CCL2 secretion, leading to enhanced macrophage infiltration.
• Pharmacological inhibition of STING with H151 significantly reduced macrophage infiltration and peritoneal fibrosis.
• STING inhibition demonstrated therapeutic potential in ameliorating EPS.

Conclusions:

• The STING signaling pathway is a critical mediator in the pathogenesis of EPS.
• STING inhibitors represent a promising therapeutic strategy for preventing or reversing EPS.
• Targeting the STING pathway could benefit patients undergoing peritoneal dialysis.